These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 38053842)
1. Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas. Wang C; He Z Front Pharmacol; 2023; 14():1276466. PubMed ID: 38053842 [No Abstract] [Full Text] [Related]
2. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma. Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778 [No Abstract] [Full Text] [Related]
3. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery. Yin X; Li M; He Z Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061 [TBL] [Abstract][Full Text] [Related]
4. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer. Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225 [TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas. Zhang G; Tai P; Fang J; Chen A; Chen X; Cao K Front Oncol; 2023; 13():1157115. PubMed ID: 37051542 [TBL] [Abstract][Full Text] [Related]
6. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing. Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991 [TBL] [Abstract][Full Text] [Related]
7. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer. Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067 [TBL] [Abstract][Full Text] [Related]
8. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863 [TBL] [Abstract][Full Text] [Related]
9. Identification of EMT-Related Genes and Prognostic Signature With Significant Implications on Biological Properties and Oncology Treatment of Lower Grade Gliomas. Wu J; He J; Zhang J; Ji H; Wang N; Ma S; Yan X; Gao X; Du J; Liu Z; Hu S Front Cell Dev Biol; 2022; 10():887693. PubMed ID: 35656554 [TBL] [Abstract][Full Text] [Related]
10. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Gao B; Wang Y; Lu S Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232 [TBL] [Abstract][Full Text] [Related]
11. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature. Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598 [TBL] [Abstract][Full Text] [Related]
12. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas. Luo C; Liu Z; Ye W; Liu F Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164 [No Abstract] [Full Text] [Related]
13. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. Li Y; Feng Y; Luo F; Peng G; Li Y Front Immunol; 2022; 13():1089792. PubMed ID: 36726969 [TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
15. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
17. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma. Zhou Y; Li G; Li H; Lai F; Duan P; Cheng M J Immunol Res; 2022; 2022():1377565. PubMed ID: 35836470 [TBL] [Abstract][Full Text] [Related]
18. Identification and validation of biomarkers for epithelial-mesenchymal transition-related cells to estimate the prognosis and immune microenvironment in primary gastric cancer by the integrated analysis of single-cell and bulk RNA sequencing data. Shen K; Ke S; Chen B; Zhang T; Wang H; Lv J; Gao W Math Biosci Eng; 2023 Jun; 20(8):13798-13823. PubMed ID: 37679111 [TBL] [Abstract][Full Text] [Related]
19. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas. Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y Front Immunol; 2023; 14():1102094. PubMed ID: 37153540 [TBL] [Abstract][Full Text] [Related]